Rani Therapeutics Holdings Income Statement (2020-2026) | RANI

Income Statement Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
1.96M1.03M0.17M1.46M1.71M
Operating items
Research & Development (Quarter)
3.76M11.96M7.42M7.59M9.53M9.10M10.39M9.71M11.09M11.22M7.61M7.59M6.12M6.17M6.81M6.57M5.50M3.22M4.91M5.16M
Selling, General & Administrative (Quarter)
3.46M15.82M5.95M6.19M6.32M7.24M7.10M6.80M7.21M6.63M5.83M6.45M6.41M5.63M5.46M5.62M5.00M4.04M5.09M4.89M
Other Operating Expenses (Quarter)
3.71M
Operating Expenses (Quarter)
7.22M27.78M13.36M13.78M15.85M16.34M17.48M16.52M18.29M17.86M13.43M14.03M12.52M11.80M15.99M12.19M10.51M7.26M10.00M10.05M
Operating Income (Quarter)
-5.26M-27.78M-13.36M-13.78M-15.85M-16.34M-17.48M-16.52M-18.29M-17.86M-13.43M-14.03M-12.52M-11.80M-14.96M-12.01M-10.51M-7.26M-8.54M-8.34M
EBIT (Quarter)
-5.26M-27.78M-13.36M-13.78M-15.85M-16.34M-17.48M-16.52M-18.29M-17.86M-13.43M-14.03M-12.52M-11.80M-14.96M-12.01M-10.51M-7.26M-8.54M-8.34M
Non-operating items
Interest & Investment Income (Quarter)
0.01M0.01M0.02M0.01M0.04M0.38M0.82M0.89M0.90M0.84M0.68M0.55M0.44M0.41M0.36M0.22M0.16M0.07M0.38M0.41M
Other Non Operating Income (Quarter)
-0.70M1.40M
Net income details
EBT (Quarter)
-5.48M-28.66M-13.35M-13.77M-15.81M-16.32M-17.38M-16.83M-18.66M-18.33M-14.05M-14.78M-13.36M-12.72M-15.72M-12.74M-11.22M-7.91M-8.50M-8.02M
Tax Provisions (Quarter)
0.00M0.04M-0.04M0.06M0.15M-0.11M-0.04M
Profit After Tax (Quarter)
-5.49M-3.14M31.45M-13.83M-15.97M-7.96M15.41M-16.83M-18.66M-18.33M-14.05M-14.78M-13.36M-6.78M-8.95M-12.74M-11.22M-5.41M-10.30M-8.02M
Income from Non-Controlling Interests (Quarter)
-5.49M-25.56M-8.12M-7.61M-8.34M-8.25M-8.56M-8.46M-9.36M-9.13M-6.96M-7.30M-6.56M-5.94M-6.78M-5.47M-4.53M-2.50M1.23M-0.98M
Income from Continuing Operations (Quarter)
-5.49M-28.70M-13.30M-13.83M-15.97M-16.21M-17.34M-16.83M-18.66M-18.33M-14.05M-14.78M-13.36M-12.72M-15.72M-12.74M-11.22M-7.91M-8.50M-8.02M
Consolidated Net Income (Quarter)
-5.49M-28.70M-13.30M-13.83M-15.97M-16.21M-17.34M-16.83M-18.66M-18.33M-14.05M-14.78M-13.36M-12.72M-15.72M-12.74M-11.22M-7.91M-8.50M-8.02M
Income towards Parent Company (Quarter)
-5.49M-28.70M-13.30M-13.83M-15.97M-16.21M-17.34M-16.83M-18.66M-18.33M-14.05M-14.78M-13.36M-12.72M-15.72M-12.74M-11.22M-7.91M-8.50M-8.02M
Net Income towards Common Stockholders (Quarter)
-5.49M-28.70M-13.30M-13.83M-15.97M-16.21M-17.34M-16.83M-18.66M-18.33M-14.05M-14.78M-13.36M-12.72M-15.72M-12.74M-11.22M-7.91M-8.50M-8.02M
Additional items
EPS (Basic) (Quarter)
-0.12-0.16-0.270.290.310.33-2.21-0.33-0.37-0.36-0.27-0.29-0.26-0.24-0.27-0.22-0.18-0.120.05-0.04
EPS (Weighted Average and Diluted) (Quarter)
-0.16-0.270.290.310.33-2.21-0.33-0.37-0.36-0.27-0.29-0.26-0.24-0.27-0.22-0.18-0.120.05-0.04
Shares Outstanding (Weighted Average) (Quarter)
46.90M19.44M0.02M21.41M24.37M23.45M0.02M25.24M25.34M25.55M0.03M26.03M26.32M27.07M0.03M33.44M35.00M76.34M131.57M180.00M
Shares Outstanding (Diluted Average) (Quarter)
19.44M0.02M21.41M22.93M24.47M0.02M25.24M25.29M25.38M0.03M26.03M26.18M28.84M0.03M33.44M36.54M46.44M0.07M180.00M
EBITDA (Quarter)
-5.26M-27.78M-13.36M-13.78M-15.85M-16.34M-17.48M-16.52M-18.29M-17.86M-13.43M-14.03M-12.52M-11.80M-14.96M-12.01M-10.51M-7.26M-8.54M-8.34M
Interest Expenses (Quarter)
0.17M0.11M-0.00M0.35M0.72M1.21M1.27M1.32M1.30M1.29M1.28M1.34M1.12M0.94M0.88M0.72M0.35M0.09M
Shares Outstanding (Quarter)
46.90M29.29M29.29M24.77M24.66M24.72M25.30M25.38M24.12M25.88M26.04M24.12M26.49M24.12M23.97M33.57M47.94M47.94M97.62M23.97M
Tax Rate (Quarter)
-0.02-0.130.30-0.46-0.970.650.24